Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma.
Hepatitis B virus (HBV) carriers are at high risk for the development of hepatocellular carcinoma (HCC), but there are no reliable markers that will identify such high-risk carriers. The objective of this work is to identify serologic markers that may indicate the early presence of HCC. Since HBV-encoded X antigen (HBxAg) likely contributes to HCC by up- or down-regulation of host gene expression, X positive and negative HepG2 cells were made and subjected to cDNA subtraction. When specific ELISAs were constructed measuring differentially expressed antigens and corresponding antibodies, antibodies to several differentially expressed genes were detected. In cross-sectional and longitudinal studies, antibodies were predominantly present in patients with HBV-associated cirrhosis and HCC, but not in most carriers with hepatic inflammation alone or without active liver disease. Antibodies were also present in patients with hepatitis C virus (HCV)-related HCC, but rarely detected in sera from uninfected individuals, those with tumors other than HCC, or those with drug-induced hepatitis. Statistical analysis showed that HCC patients with four or more antibodies detectable before the appearance of HCC had decreased survival, suggesting that these markers may reflect stepwise hepatocarcinogenesis. Hence, these antibodies may serve as preneoplastic markers for HCC in HBV carriers with chronic liver disease, and may be identified by a simple blood test.
Hann
Hie-Won L
HW
Department of Medicine, Division of Gastroenterology and Hepatology, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Lee
Jungmin
J
Bussard
Anne
A
Liu
Catherine
C
Jin
Yongri R
YR
Guha
Koel
K
Clayton
Marcia M
MM
Ardlie
Kristin
K
Pellini
Michael J
MJ
Feitelson
Mark A
MA
D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D000918:Antibody Specificity; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000276:immunology / Q000821:virology*; D003430:Cross-Sectional Studies; D018076:DNA, Complementary / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000150:complications / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000276:immunology / Q000821:virology*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D011230:Precancerous Conditions / Q000097:blood / Q000276:immunology / Q000821:virology*; D015534:Trans-Activators / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D015854:Up-Regulation; D054334:Viral Regulatory and Accessory Proteins
D014408:Biomarkers, Tumor; D018076:DNA, Complementary; D006510:Hepatitis B Antibodies; D015534:Trans-Activators; D054334:Viral Regulatory and Accessory Proteins; C057628:hepatitis B virus X protein